MX2021008386A - Compuesto interno de sulfiamidina amida-aril amida cíclica y su uso para el tratamiento de la hepatitis b. - Google Patents

Compuesto interno de sulfiamidina amida-aril amida cíclica y su uso para el tratamiento de la hepatitis b.

Info

Publication number
MX2021008386A
MX2021008386A MX2021008386A MX2021008386A MX2021008386A MX 2021008386 A MX2021008386 A MX 2021008386A MX 2021008386 A MX2021008386 A MX 2021008386A MX 2021008386 A MX2021008386 A MX 2021008386A MX 2021008386 A MX2021008386 A MX 2021008386A
Authority
MX
Mexico
Prior art keywords
amide
treating hepatitis
sulphiamidine
compound
internal cyclic
Prior art date
Application number
MX2021008386A
Other languages
English (en)
Inventor
Zhe Wang
Lei Zhang
Zhihong Zeng
Original Assignee
Shanghai Longwood Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Longwood Biopharmaceuticals Co Ltd filed Critical Shanghai Longwood Biopharmaceuticals Co Ltd
Publication of MX2021008386A publication Critical patent/MX2021008386A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a un compuesto interno de sulfiamidina amida-aril amida cíclica y un uso del mismo para tratar la hepatitis B. Específicamente, se describe un compuesto que puede actuar como un inhibidor de la replicación del VHB y que tiene una estructura representada por la fórmula química (L), o un estereoisómero o tautómero del mismo, o una sal, un hidrato o un solvato farmacéuticamente aceptable del mismo. Consulte la descripción para obtener definiciones detalladas de cada grupo. La presente invención también se refiere a una composición farmacéutica que contiene el compuesto y un uso del mismo para tratar la hepatitis B. (VER FORMULA).
MX2021008386A 2019-01-11 2020-01-10 Compuesto interno de sulfiamidina amida-aril amida cíclica y su uso para el tratamiento de la hepatitis b. MX2021008386A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910027573.6A CN111434665B (zh) 2019-01-11 2019-01-11 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
PCT/CN2020/071523 WO2020143798A1 (zh) 2019-01-11 2020-01-10 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途

Publications (1)

Publication Number Publication Date
MX2021008386A true MX2021008386A (es) 2021-11-17

Family

ID=71520539

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008386A MX2021008386A (es) 2019-01-11 2020-01-10 Compuesto interno de sulfiamidina amida-aril amida cíclica y su uso para el tratamiento de la hepatitis b.

Country Status (12)

Country Link
US (1) US20220380384A1 (es)
EP (1) EP3909957A4 (es)
JP (1) JP2022517984A (es)
KR (1) KR102650441B1 (es)
CN (2) CN111434665B (es)
AU (1) AU2020205923B2 (es)
BR (1) BR112021013730A2 (es)
CA (1) CA3126570A1 (es)
MX (1) MX2021008386A (es)
SG (1) SG11202107643YA (es)
WO (1) WO2020143798A1 (es)
ZA (1) ZA202105438B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115160344A (zh) * 2021-04-06 2022-10-11 上海长森药业有限公司 通过口服给药抑制CD4+Treg细胞的药物和方法
CN115177624A (zh) * 2021-04-06 2022-10-14 上海长森药业有限公司 通过口服给药增加病毒空衣壳蛋白治疗hbv的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103889953B (zh) 2011-07-01 2016-06-08 巴鲁﹒S﹒布隆伯格研究所 作为防乙型肝炎病毒感染的抗病毒剂的氨磺酰苯甲酰胺衍生物
KR20190007106A (ko) 2011-12-21 2019-01-21 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
CN110483484A (zh) * 2014-02-06 2019-11-22 爱尔兰詹森科学公司 氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
EP3129387B1 (en) * 2014-04-11 2019-06-26 Bayer Pharma Aktiengesellschaft Novel macrocyclic compounds
US10875876B2 (en) * 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108250121A (zh) * 2016-12-28 2018-07-06 上海长森药业有限公司 磺酰胺-芳基酰胺类化合物及其治疗乙型肝炎的药物用途
CN108264520B (zh) * 2017-01-03 2021-12-07 上海长森药业有限公司 用于治疗乙型肝炎的化合物及其用途
CN108341810B (zh) * 2017-01-23 2022-01-18 上海长森药业有限公司 环硫脲类化合物及其用途
CN108456216B (zh) * 2017-02-22 2021-12-28 上海长森药业有限公司 磺酰肼类化合物及其用途
CN109251212A (zh) * 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN109251158B (zh) * 2017-07-14 2023-05-23 上海长森药业有限公司 硫脒酰胺类化合物及其用于乙型肝炎治疗的用途

Also Published As

Publication number Publication date
WO2020143798A1 (zh) 2020-07-16
BR112021013730A2 (pt) 2021-09-21
US20220380384A1 (en) 2022-12-01
AU2020205923B2 (en) 2022-12-01
CN113286798B (zh) 2022-08-02
AU2020205923A1 (en) 2021-08-26
CN111434665A (zh) 2020-07-21
EP3909957A4 (en) 2022-09-07
CN111434665B (zh) 2023-03-10
CN113286798A (zh) 2021-08-20
KR20210134621A (ko) 2021-11-10
CA3126570A1 (en) 2020-07-16
ZA202105438B (en) 2022-09-28
JP2022517984A (ja) 2022-03-11
SG11202107643YA (en) 2021-08-30
KR102650441B1 (ko) 2024-03-21
EP3909957A1 (en) 2021-11-17

Similar Documents

Publication Publication Date Title
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
MX2021010242A (es) Compuesto inhibidor de jak y uso del mismo.
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
EA202090530A1 (ru) Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
TW200616979A (en) Non-nucleoside reverse transcriptase inhibitors
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
EA202190657A1 (ru) Ингибиторы саркомера сердца
PH12019550083A1 (en) Inhibitors of bruton's tyrosine kinase
EA201992771A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2021008386A (es) Compuesto interno de sulfiamidina amida-aril amida cíclica y su uso para el tratamiento de la hepatitis b.
PH12017502254B1 (en) Pyrazole derivative or pharmaceutically acceptable salt thereof
MX2021002188A (es) Nuevo derivado de amina heterociclica y composicion farmaceutica que la comprende.
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2017012238A (es) Inhibidores de la polimerasa del virus de la hepatitis c.
PH12020551117A1 (en) Compositions for preventing or treating uveitis